<DOC>
	<DOC>NCT01243944</DOC>
	<brief_summary>This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in subjects with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).</brief_summary>
	<brief_title>Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Subjects diagnosed with PV for at least 24 weeks prior to screening according to the 2008 World Health Organization criteria Subjects resistant to or intolerant of hydroxyurea Subjects with a phlebotomy requirement Subjects with splenomegaly (palpable or nonpalpable) and a spleen volume, as measured by MRI (or CT in applicable subjects), of greater than or equal to 450 cubic centimeters Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 Women who are pregnant or nursing Subjects with inadequate liver or renal function Subjects with significant bacterial, fungal, parasitic, or viral infection requiring treatment Subjects with an active malignancy within the past 5 years, excluding specific skin cancers Subjects with known active hepatitis or HIV positivity Subjects who have previously received treatment with a JAK inhibitor Subjects being treated with any investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>INCB018424</keyword>
</DOC>